Back to Search Start Over

Science 37 taps a SPAC to go public, with siteless trial specialist valued at a cool $1B.

Authors :
Adams, Ben
Source :
FierceBiotech; 5/7/2021, pN.PAG-N.PAG, 1p
Publication Year :
2021

Abstract

Science 37 had a good year in 2020, using its hybrid trial approach to help companies navigate their way through a pandemic; it's now hoping to top 2020 with a major public listing in 2021. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
GOING public (Securities)
PANDEMICS

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
150235205

Tools

Authors Abstract Subjects Details